- Dose reduction of the biologic therapies adalimumab, etanercept, and ustekinumab demonstrated noninferiority to usual care for QoL, but not disease activity, in this randomized clinical trial.
Why this matters
- Achieving the lowest effect dose may help reduce the risk for and financial burden of biologic therapy.
- 53% of patients in the dose-reduction group successfully tapered their dose at 12 months, with no related serious adverse events reported.
- Dose reduction did not meet the noninferiority criteria for disease activity at 12 months compared with usual care (mean Psoriasis Area and Severity Index, 3.4 vs 2.1).
- Dose reduction met noninferiority criteria for QoL at 12 months compared with usual care (median Dermatology Life Quality Index score, 1.0 vs 0.0).
- Dose reduction and usual care were associated with a similar number of persistent flares (5 in each group).
- 111 patients with plaque psoriasis and stable low disease activity, 53 who underwent dose reduction and 58 who maintained usual care, were included.
- Funding: ZonMw.
- Open-label design.